で公開中です！詳しく見る

SCYNEXIS

SCYX

時価総額 $3652万

3.67 USD

-0.24

6.14%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

3.59

-0.08

2.18%

1日

-6.14%

5日間

-9.38%

1か月

-10.71%

3か月

-18.08%

6か月

-56.31%

年初来

-28.18%

1年

-42.66%

5年間

-91.64%

10年間

-98.82%

概要： SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

従業員数： 29

ヘルスケア医薬品メーカー（スペシャリティ・ジェネリック）

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ニュートラル

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to advance the development of SCY-247, the Company's second-generation fungerp antifungal candidate.

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

ニュートラル

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K.

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.

ニュートラル

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D.

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

ニュートラル

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

ニュートラル

SCYNEXIS to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:

SCYNEXIS to Participate in Upcoming Investor Conferences

ニュートラル

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of the Senior Director's employment with the Company, as a material inducement to the employee's acceptance of employment, and was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

ニュートラル

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator.

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ニュートラル

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026

SCYNEXIS Announces One-for-Eight Reverse Stock Split

ニュートラル

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026.

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています